Literature DB >> 33722885

Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.

Mohammad H Al-Shaer1,2, Carolyn D Philpott3,4, Christopher A Droege5,4, Joshua D Courter6, Daniel P Healy4, Molly E Droege5,4, Neil E Ernst5,4, Eric W Mueller5,4, Charles A Peloquin1,2.   

Abstract

Sepsis causes half of acute kidney injuries in the intensive care unit (ICU). ICU patients may need continuous renal replacement therapy (CRRT), which will affect their antimicrobial exposure. We aimed to build a cefepime population pharmacokinetic (PK) model in CRRT ICU patients and perform simulations to assess target attainment. Patients who were ≥18 years old, were admitted to the ICU, and received cefepime 2 g every 8 h as a 4-h infusion while on CRRT were enrolled prospectively. Samples were collected from the predialyzer ports, postdialyzer ports, and effluent fluid at 1, 2, 3, 4, and 8 h after the first dose and at steady state. Age, sex, weight, urine output, and CRRT parameters were recorded. Pmetrics was used for population PK and simulations. The target exposure was 100% of the dosing interval during which the free beta-lactam concentration is above the MIC (fT >MIC). Ten patients were included; their mean age was 53 years, and mean weight was 119 kg. Seventy percent were males. Cefepime was described by a five-compartment model. The downtime was applied to the CRRT flow rates, which were used to describe the rates of transfer between the compartments. At MICs of ≤8 mg/liter, intermittent infusion of 2 g cefepime every 8 h achieved good target attainment both early in therapy and at steady state. Only extended- and continuous-infusion regimens achieved good target attainment at MICs of 16 mg/liter. In conclusion, 2 g cefepime infused over 30 min followed by extended infusion of 2 g every 8 h achieved good target attainment at MICs of ≤16 mg/liter with different CRRT flow rates and may be considered in resistant bacterial infections.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  CRRT; Monte Carlo simulation; cefepime; population pharmacokinetics

Year:  2021        PMID: 33722885     DOI: 10.1128/AAC.00144-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

2.  Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy.

Authors:  Mohammad H Al-Shaer; Kelly Maguigan; Jennifer Ashton; Veena Venugopalan; Molly E Droege; Carolyn D Philpott; Christopher A Droege; Daniel P Healy; Eric W Mueller; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.